Skip to main content

iwCLL 2023 Main banner

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

A
1207
A matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA: acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naïve chronic lymphocytic leukemia
Therapy of CLL

Favorite
2005
A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies
Clinical Challenges in CLL

Favorite
3004
A Phase 2 Study of Minimal Residual Disease-Guided, Time-Limited, First-Line Therapy of Chronic Lymphocytic Leukemia with Pirtobrutinib and Venetoclax (MIRACLE)
Therapy of CLL

Favorite
2009
A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL
Therapy of CLL

Favorite
1210
A Phase II study of intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Therapy of CLL

Favorite
1158
A retrospective study evaluating the sequence of BTKi and venetoclax, with a focus on toxicity
Therapy of CLL

Favorite
1229
A Study of Frontline Therapy in Adults Aged 80+ Years with Chronic Lymphocytic Leukemia (CLL)
Therapy of CLL

Favorite
1037
Activation of S100-A9/EMMPRIN axis triggers survival/proliferation pathways in leukemic cells. A novel target for chronic lymphocytic leukemia
Pathogenesis of CLL

Favorite
1213
An examination of health literacy amongst patients with Chronic Lymphocytic Leukemia- A study from The Lymphoma Coalition Global Patient Survey 2022.
Past, Present, and Future in CLL

Favorite
1214
An Investigation into the Differences between Western and Chinese population with Chronic Lymphocytic Leukemia
Therapy of CLL

Favorite
3008
An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL)
Therapy of CLL

Favorite
1223
Anti-CD19 CAR T-cell therapy for patients with Richter syndrome: A LYSA Study from the DESCAR-T Registry
Therapy of CLL

Favorite
1123
Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study
Clinical Challenges in CLL

Favorite
1041
Anti-FcμR Antibody Drug Conjugate as a Potential Therapeutic Agent for the Treatment of Chronic Lymphocytic Leukemia
Therapy of CLL

Favorite
1101
Association between hypertension and overall survival in chronic lymphocytic leukemia
Clinical Challenges in CLL

Favorite